Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Ingresos
9
9
10
9
9
13
Crecimiento de los Ingresos (YoY)
-10%
-10%
11%
0%
-31%
44%
Costo de los ingresos
7
7
7
5
8
7
Utilidad bruta
2
1
2
3
1
5
Venta, General y Administración
6
7
7
8
7
8
Investigación y Desarrollo
1
1
1
2
2
2
Gastos de Operación
8
8
8
10
10
10
Otras Ingresos (Gastos) No Operativos
0
0
0
0
0
0
Ingreso antes de impuestos
-15
-18
-11
-11
-16
-10
Gasto por Impuesto a la Renta
--
--
--
--
--
0
Ingreso Neto
-14
-17
-11
-11
-16
-9
Crecimiento de la Utilidad Neta
0%
55%
0%
-31%
78%
-77%
Acciones en Circulación (Diluidas)
4.02
2.36
0.55
0.26
0.14
0.06
Cambio de Acciones (YoY)
222%
331%
112%
86%
133%
50%
EPS (Diluido)
-3.66
-7.59
-20.49
-43.76
-116.78
-158.33
Crecimiento de EPS
-68%
-63%
-53%
-63%
-26%
-84%
Flujo de efectivo libre
-4
-5
-7
-6
-14
-3
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
22.22%
11.11%
20%
33.33%
11.11%
38.46%
Margen de operación
-66.66%
-66.66%
-60%
-77.77%
-88.88%
-30.76%
Margen de beneficio
-155.55%
-188.88%
-110%
-122.22%
-177.77%
-69.23%
Margen de flujo de caja libre
-44.44%
-55.55%
-70%
-66.66%
-155.55%
-23.07%
EBITDA
-5
-5
-6
-7
-8
-4
Margen de EBITDA
-55.55%
-55.55%
-60%
-77.77%
-88.88%
-30.76%
D&A para EBITDA
1
1
0
0
0
0
EBIT
-6
-6
-6
-7
-8
-4
Margen de EBIT
-66.66%
-66.66%
-60%
-77.77%
-88.88%
-30.76%
Tasa de Impuesto Efectiva
--
--
--
--
--
0%
Estadísticas clave
Cierre Anterior
$0.0001
Precio de apertura
$0
Rango del día
$0 - $0
Rango de 52 semanas
$0 - $0.0003
Volumen
331
Volumen promedio
396
EPS (TTM)
-5.00
Rendimiento de dividendos
--
Cap. de mercado
$1.5K
¿Qué es THMO?
ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. The company is headquartered in Rancho Cordova, California and currently employs 25 full-time employees. The firm provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The firm markets and sells its medical device products through independent distributors.